BioDelivery Sciences International Stock Forecast, Price & News

-0.09 (-2.47 %)
(As of 06/21/2021 12:07 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume5,234 shs
Average Volume1.04 million shs
Market Capitalization$349.87 million
P/E Ratio14.20
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BioDelivery Sciences International and its competitors with MarketBeat's FREE daily newsletter.

BioDelivery Sciences International logo

About BioDelivery Sciences International

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film to treat opioid dependence; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. The company also offers Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.59 out of 5 stars

Medical Sector

5th out of 2,100 stocks

Pharmaceutical Preparations Industry

3rd out of 831 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

Is BioDelivery Sciences International a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioDelivery Sciences International stock.
View analyst ratings for BioDelivery Sciences International
or view top-rated stocks.

What stocks does MarketBeat like better than BioDelivery Sciences International?

Wall Street analysts have given BioDelivery Sciences International a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioDelivery Sciences International wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioDelivery Sciences International's next earnings date?

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for BioDelivery Sciences International

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its earnings results on Thursday, May, 6th. The specialty pharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by $0.02. The specialty pharmaceutical company earned $41.02 million during the quarter, compared to analysts' expectations of $40.99 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 26.13% and a net margin of 16.32%.
View BioDelivery Sciences International's earnings history

How has BioDelivery Sciences International's stock been impacted by Coronavirus?

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BDSI shares have decreased by 8.1% and is now trading at $3.64.
View which stocks have been most impacted by COVID-19

What guidance has BioDelivery Sciences International issued on next quarter's earnings?

BioDelivery Sciences International updated its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $170 million-$180 million, compared to the consensus revenue estimate of $179.53 million.

What price target have analysts set for BDSI?

2 Wall Street analysts have issued 12-month price objectives for BioDelivery Sciences International's stock. Their forecasts range from $5.50 to $6.25. On average, they anticipate BioDelivery Sciences International's share price to reach $5.88 in the next year. This suggests a possible upside of 61.4% from the stock's current price.
View analysts' price targets for BioDelivery Sciences International
or view top-rated stocks among Wall Street analysts.

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the following people:
  • Mr. Jeffrey Allen Bailey, CEO & Director (Age 58, Pay $599.96k)
  • Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 56, Pay $629.46k)
  • Ms. Mary Theresa Coelho, Exec. VP, CFO & Treasurer (Age 59, Pay $657.17k)
  • Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52, Pay $586.68k)
  • Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 60, Pay $570.06k)
  • Mr. Joseph M. Lockhart, Sr. VP of Operations
  • Mr. Kevin Ostrander, Sr. VP of Bus. Devel.
  • Dr. Bill McCarberg, Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
  • Dr. Arthur G. Lipman PharmD, Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
  • Dr. Jeff Katz, Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board

Who are some of BioDelivery Sciences International's key competitors?

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), (JD), Baidu (BIDU), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

Who are BioDelivery Sciences International's major shareholders?

BioDelivery Sciences International's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.52%), Wasatch Advisors Inc. (5.57%), Systematic Financial Management LP (3.46%), Goldman Sachs Group Inc. (2.83%), HealthInvest Partners AB (1.98%) and Royce & Associates LP (1.91%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Jeffrey Allen Bailey, Kevin Kotler, Mark A Sirgo, Mary Theresa Coelho, Scott M Plesha, Thomas B Smith and W Mark Watson.
View institutional ownership trends for BioDelivery Sciences International

Which major investors are selling BioDelivery Sciences International stock?

BDSI stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Nuveen Asset Management LLC, Millennium Management LLC, Renaissance Technologies LLC, D. E. Shaw & Co. Inc., Los Angeles Capital Management LLC, Man Group plc, and Zebra Capital Management LLC. Company insiders that have sold BioDelivery Sciences International company stock in the last year include James Vollins, Jeffrey Allen Bailey, Mark A Sirgo, Mary Theresa Coelho, and W Mark Watson.
View insider buying and selling activity for BioDelivery Sciences International
or view top insider-selling stocks.

Which major investors are buying BioDelivery Sciences International stock?

BDSI stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, Goldman Sachs Group Inc., Wasatch Advisors Inc., Brown Advisory Inc., Hillsdale Investment Management Inc., HealthInvest Partners AB, BlackRock Inc., and Stanley Laman Group Ltd..
View insider buying and selling activity for BioDelivery Sciences International
or or view top insider-buying stocks.

How do I buy shares of BioDelivery Sciences International?

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioDelivery Sciences International's stock price today?

One share of BDSI stock can currently be purchased for approximately $3.64.

How much money does BioDelivery Sciences International make?

BioDelivery Sciences International has a market capitalization of $358.74 million and generates $156.47 million in revenue each year. The specialty pharmaceutical company earns $25.71 million in net income (profit) each year or $0.24 on an earnings per share basis.

How many employees does BioDelivery Sciences International have?

BioDelivery Sciences International employs 176 workers across the globe.

What is BioDelivery Sciences International's official website?

The official website for BioDelivery Sciences International is

Where are BioDelivery Sciences International's headquarters?

BioDelivery Sciences International is headquartered at 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.